SRNE - The Buzz Show: Sorrento Therapeutics (NASDAQ: SRNE) Reports Positive Results from COVI-MSC Study

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Sorrento Therapeutics Reports Positive Results from COVI-MSC Study

Sorrento Therapeutics (NASDAQ: SRNE) rose 28% by midday after the company announced positive preliminary results of its Phase 1b Study of COVI-MSC for Treatment of ICU COVID-19 Patients.

The first three patients enrolled tolerated treatment well and improved rapidly while no infusion-related adverse events noted for any patient treated to date and additional enrollment continues.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T ”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir ”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD , COVI-AMG , COVI-SHIELD , Gene-MAb , COVI-MSC and COVI-DROPS ; and diagnostic test solutions, including COVI-TRACK , COVI-STIX and COVI-TRACE .

For more information, please visit: Sorrento Therapeutics, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Sorrento Therapeutics (NASDAQ: SRNE) Reports Positive Results from COVI-MSC Study first appeared on Financial Buzz .

For further details see: